DAFTAR PUSTAKA

AABB, 2005. *Technical Manual* 15th ed. AABB, Bethesda. pp: 139-158,175-202, 361-383,483-519.

American Red Cross. 2018. *Blood Needs and Blood Supply*. Diunduh dari: https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html**,** 8 November 2018.

Apelseth, T.O., Bruserud, O., Wentzel-Larsen, T., Hervig, T. 2010. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. *Transfusion*, 50(4):766–775.

Aubron, C., Flint, A.W.J., Ozier, Y., McQuilten, Z. 2018. Platelet storage duration and its clinical and transfusion outcomes: a systematic review. *Critical Care*; 22:185.

Avvisati, G., Tirindelli, M.C., Annibali, O. 2003. Thrombocytopenia and hemorrhagic risk in cancer patients. *Crit Rev Oncol Hematol*, 48(Suppl):S13–S16.

Bayer, W.L., Bodensteiner, D.C., Tilzer, L.L., Adams, M.E. 1992. Use of platelets and other transfusion products in patients with malignancy. *Seminars in Thrombosis and Hemostasis*, 18:380–391.

Berger, G., Hartwell, D.W., Wagner, D.D. 2008. P-selectin and platelet clearance. *Blood*, 92:4446-52.

Bikker, A., Bouman, E., Sebastian, S., Suzanne, J.A., Urbanus, R.T., Fijnheer, R., Boven, L.A., Roest, M. 2016. Functional recovery of stored platelets after transfusion. *Transfusion*, 5(6):1030–1037

Bishop, J.F., Matthews, J.P., McGrath, K. 1991.Factors influencing 20-hour increments after platelet transfusion. *Transfusion*, 31:392-396.

Bishop, l.F., McGrath, K., Wolf, M.M., *et al*. 1998. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 71:383-387.

Blajchman, M.A. 2008. *Platelet transfusions: an historical perspective*. HematologyAm Soc Hematol Educ Program. 197.

Blann, A.D., Sunil, K., Gregory, Y.H. 2003. The adhesion molecule P-selectin and cardiovascular disease. *European Heart Journal*, 24:2166–2179.

British Committee for Standards in Haematology (BCSH). 2003. Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. *Br J Haematol.*, 122(1):10-23.

Brown, C.J. & Navarrete, C.V. 2011. Clinical relevance of the HLA system in blood transfusion. *Vox Sanguinis*, 101,93–105

Brubaker, D.B., Marcus, C., Holmes, E. 1998. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic

patients transfused with single donor platelets. *American Journal of Hematology*, 58, 165–176.

Castaman, G. dan Pieri, L. 2018. Management of thrombocytopenia in cancer. *Thromb Res*, 164(1):89-93.

CLSI, 2010. *Validation, Verification and Quality assurance of Automated Hematology Analyzers; Approved Standard* 2nd Ed, CLSI document H26-P2. Wayne,Pennsylvania. pp:2-26

Cushing, M.M. 2013. *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects*, chapter Platelet Products. Elsevier, San Diego

Daly, P.A., Schiffer, C.A., Aisner, J., Wiernik, P.H. 1980. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. *JAMA*, 243(5):435–438.

David, G. dan Patrono, C. 2008. Platelet activation and atherothrombosis. *N Engl J Med*, 357(24):2482-94.

Delaflor-Weiss, E. & Mintz, P.D., 2000. The Evaluation and Management of Platelet Refractoriness and Alloimmunization. *Transfus Med Rev*, 14(2):180–196.

Desborough, M., Estcourt, L.J., Doree, C., Trivella, M., Hopewell, S., Stanworth, S.J., Murphy, M.F. 2016. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. *Cochrane Database Syst Rev*, 22(8): CD010982.

Devine, D.V. dan Serrano, K. 2010. The platelet storage lesion. *Clin Lab Med*, 30:475-87.

Dijkstra-Tiekstra, M.J., van de Watering, L.M., Rondeel, J.M., Slomp, J., de Wildt-Eggen, J. 2014. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation. *Transfus Med*; 24(2):99–104.

Doughty, H., Murphy, M., Metcalfe, P., Rohatiner, A., Lister, T., Waters, A. 1994. Relative importance of immune and non-immune causes of platelet refractoriness. *Vox Sanguinis*, 66, 200–205.

Doughty, H.A., Murphy, M.F., Metcalfe, P., Rohatiner, A.Z., Lister, T.A. & Waters, A.H. 1994. Relative importance of immune and non-immune causes of platelet refractoriness. *Vox Sanguinis*, 66, 200–205

Elstad, M.R., McIntyre, T.M., Prescott, S.M., Zimmerman, G.A. 2015. The interaction of leukocytes with platelets in blood coagulation. *Curr Opin Hematol*., 2:47.

Elting, L.S., Rubenstein, E.B., Martin, C.G., Kurtin, D., Rodriguez, S., Laiho, E., *et al*. 2011. Incidence, Cost, and Outcomes of Bleeding and

Chemotherapy Dose Modification among Solid Tumor Patients with Chemotherapy-Induced Thrombocytopenia. *J Clin Oncol*; 19:1137-46.

Enright, H., Gernsheimer, T., McCullough, J., *et al.* 1997. Moderate to severe reactions to platelet transfusion: Experience of the TRAP multicenter trial. *Blood*, 90: 1172A. (abstr)

Ferroni, P., Guadagni, F., Riondino, S., *et al*. 2014. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. *Haematologica*, 99(10):1638–1644.

Fijnheer R, Modderman PW, Veldman H, *et al*. 1990. Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion, 30:20-5

Freynhofer, M.K., Gruber, S.C., Grove, E.L., Weiss, T.W., Wojta, T.W., Huber, K. 2015. Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. *Thrombosis and Haemostasis*, 114(3): 459–468.

Friedberg, R.C. dan Mintz, P.D. 2005. Causes of refractoriness to platelet transfusion. *CUff Opin Hematol*, 2:493-498.

Fujimoto, T.T., Noda, M., Takafuta, T., *et al*. 2006. Expression and functional characterization of the P-selectin glycoprotein ligand-1 in various cells. *Int J Hematol*, 64(3-4):231–9

Funheer. R., Moddennan, P.W., Veldman, H., *et al*. 1990. Detection of platelet activation with monoclonal antibodies and flowcytometry: Changes during platelet storage. *Transfusion* 30:2025.

Ghoshal, K. dan Bhattacharyya, M. 2014. Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. *The Scientific World Journal*, 24(78):16.

Godeau, B., Fromont, P., Seror, T., *et al*. 1999, Platelet alloimmunization after multiple transfusions: A prospective study of 50 patients. , 31 :395-400.

Hamburger, S.A., McIntyre, T.M., Prescott, S.M., McEver, R.P. 1990. GMP-140 mediates adhesion of stimulated platelets to granulocytes. *Blood*, 75:550-554

Heddle, N.M., Arnold, D.M., Boye, D., Webert, K.E., Resz, I., Dumont, L.J. 2008. Comparing the eficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. *Transfusion*, 48:1447-58.

Herter, J.M., Rossaint, J. Zarbock, A. 2014. Platelets in inflammation and immunity. Journal of Thrombosis and Haemostasis, 12(11): 1764–1775.

Hill-Zobel, R.L., McCandless, B., Kang, S.A., Chikkappa, G., Tsan, M.F. 1986. Organ distribution and fate of human platelets: studies of asplenic and splenomegalic patients. *American Journal of Hematology*, 23, 231–238.

Hod, E. & Schwartz, J., 2008. Platelet Transfusion Refractoriness. *Br J haematol*; 142(3):348–60.

Hoffman, R. 2005. *Hematology: Basic Principles and Practice*. Elsevier Churchill Livingstone, Edinburgh.

Hoffmeister, K.M., Felbinger, T.W., Falet, H., *et al.* 2003. The clearance mechanism of chilled blood platelets. *Cell*, 112(1):87.

Holme, S., Sweeney, J.D., Sawyer, S., Elfath, M.D. 1997. The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. *Transfusion*, 37: 12-17.

Horvath, M., Eichelberger, B., Koren, D., Bohm, A., Ay, C., Jilma-Stohlawetz, B., 2009. Function of Platelets in Apheresis Platelet Concentrates and in Patient Blood after Transfusion as Assessed by Impact-R. *J Trans* 50:59

Hulley, S.B., Cummings, S.R., Browner, W.S., Grady, D., Newman, T.B. 2013 *Designing clinical research: an epidemiologic approach*. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, Appendix 6C, page 79

Jenne, C. N., Urrutia, R., Kubes, P. 2013. Platelets: bridging hemostasis, inflammation, and immunity," International Journal of Laboratory Hematology, 35(3): 254–261.

Johnston, G.I., Cook, R.G., McEver, R.P. 1999. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. *Cell*, 56:1033–44.

Josephson, C.D. dan Hillyer, C.D. 2004. *Handbook of Pediatric Transfusion*, chapter Blood Components. Elsevier Academic Press, Philadelphia.

Julmy, F., Ammann, R.A., Taleghani, B.M., Fontana, S., Hirt, A., Leibundgut, K. 2009. Transfusion eficacy of ABO major mismatched platelets in children is inferior to that of ABO identical platelets. *Transfusion*, 49:21–33

Kerkhoffs, J., Eikenboom, J., van de Watering, L., van Wordragen-Vlaswinkel, R.J., Wijermans, P., Brand, A. 2008. The clinical impact of platelet refractoriness: correlation with bleeding and survival. *Transfusion*, 48, 1959–1965.

Kim, S.W., dan Lim, Y.A. 2006. Establishment of reference values for platelet activation markers by flowcytometry. *Korean J Lab Med*, 26:323–328.

Kleinman, S., King, M.R., Busch, M.P., Murphy, E.L., Glynn, S.A. 2012. for The National Heart Lung and Blood Institute Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II. The NHLBI

Retrovirus Epidemiology Donor Studies (REDS and REDSII): Twenty years of research to advance blood product safety and availability. *Transfusion Medical Reviews*, 26:281–304.

Krishnamurti, C.P., Maglasang, P., Rothwell, S.W. 1999. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model. *Transfusion*, 39:967-74.

Legler, T., Fischer, I., Dittmann, J., *et al*. 1997. Frequency and causes of refractoriness in multiply transfused patients. *Annals of Hematology*, 74, 185–189.

Lim, Y.A., Cho, S.R., Lee, W.G., Park, J.S., Kim, S.W. 2008. Change of platelet activation markers using flow cytometry in patients with hematology/oncology disorders after transfusion. *Platelets*, 19(5): 328–334.

MacLennan, S., Harding, K., Llewelyn, C., Choo, L., Bakrania, L., Massey, E., Stanworth, S., Pendry, K., Williamson, L.M. 2015. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. *Transfusion*; 55(8):1856–65.

Margolin, J.F., Rabin, K.R., Steuber, P., Poplack, D.G. 2011. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG. (eds). Principles and Practice of Pediatric Oncology, 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins.

Maugeri, N., Malato, S., Femia, E.A., Pugliano, M., Campana, L., Lunghi, F., Rovere-querini, P.,Lussana, F., Podda, G., Cattaneo, M., Ciceri, F., Manfredi, A. A., 2011. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. *Blood*, 118(12), pp.3359–336

Maugeri, N., Rovere-querini, P., Evangelista, V., Covino, C., Capobianco, A., Bertilaccio, M. T. S., Piccoli, A., Totani, L., Cianflone, D., Maseri, A., Manfredi, A. A., 2009. Neutrophils phagocytose activated platelets in vivo : a phosphatidylserine , P-selectin , and ᴹʟ 2 integrin – dependent cell clearance program. *Blood Journal*, 113(21), pp.5254–5266.

McFarland, G. 1997. Laboratory investigation of drug-induced immune thrombocytopenias. *Transfus Med Rev*, 7:275-287.

McFarland, G., Anderson, A.F., Slichter, S. 1990. Factors influencing the transfusion response to HLA selected apheresis donor platelets in patient refractory to random platelet concentrates. *Br Haemato*, 73:380-386.1999

Merten, M., dan Thiagarajan, P. 2012. P-selectin expression on platelets determines size and stability of platelet aggregates. *Circulation*, 102:1931–6.

Michelson AD., Newburger PE., 2007. Platelets and Leukocytes : Aggregate Knowledge. *Blood*. 110 (3).

Michelson, A.D., Barnard, M.R., Hectman, H.B., McGregor, H., Connoly, R.J., Loscalzo, J., Valeri, C.R. 1996. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. *Proc. Natl. Acad. Sci.*, 93:11877-11882

Michelson, A.D., Barnard, M.R., Krueger, L.A. 2002. Flow cytometric analysis of platelet function. In: Gressele, P., Page, C., Fuste,r V., Vermylen, .J, editors. *Platelets in thrombotic and non-thrombotic disorders*. Cambridge University Press.

Mittal, K. dan Kaur, R. 2015. Platelet storage lesion: An update. *Asian J Tranfus Sci*, 9(1): 1-3.

Moroff, G., George, V.M., Siegl, A.M., *et al*. 2006. The inftuence of irradiation on stored platelets. *Transfusion*, 26:453-456.

Norol, F., Kuentz, M., Cordonnier, C., et al. 1994. Inftuence of clinical status on the efficiency of stored platelet transfu!;ion. *Br Haematol*., 86:125-129.

Ozaki, Y., Suzuki-Inoue, K., Inoue, O. 2013. Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. Journal of Thrombosis and Haemostasis, 11(1):330–339

Pavenski, K., Freedman, J. & Semple, J.W. 2012. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. *Tissue Antigens*, 79, 237–245.

Petz, L.D., Garratty, G., Calhoun, L., Clark, B.D., Terasaki, P.I., Gresens, C., Gornbein, J.A., Landaw, E.M., Smith, R. & Cecka, J.M. 2000. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. *Transfusion*, 40, 1446–1456.

Reimers, H.I., Kinlough-Rathbone, R.L., Cazenave, J.P., *et al*. 1973. In vitro and In vivo functions of thrombin treated platelets. *Thromb Haemos*, 35:151-66.

Ribatti, D. dan Crivellato, E. 2007. Giulio Bizzozero and the discovery of platelets. *Leukemia Research*, 31(10): 339–1341.

Rinder, H.M., Murphy, M., Mitchell, J.G., Stocks, J., Hillma, R.S. 1991. *Transfusion*, 31(5):409-414

Rinder, H.M., Murphy, M., Mitchell, l.G., *et al*. 2001 Progressive platelet activation with storage: Evidence for shortened survival of activated platelets after trdnsfusion. *Transfusion*, 31 :409-414.

Saris, A., Brinke, A.T., Middleburg, *et al*. 2018. The quality of platelet concentrates related to corrected count increment: linking in vitro to in vivo. https://doi.org/10.1111/trf.14868 (abstr)

Scheurer, M.E., Bondy, M.L., Gourney, J.G. 2012. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG. (eds). *Principles and Practice of Pediatric Oncology* 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins.

Schiffer, C.A., Anderson, K.C., Bennett, C.L., *et al*. 2001. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol, 19(5):1519-1538.

Schiffer, C.A., O'Connell, Lee, E.J. 1999. Platelet transfusion therapy for alloimmunized patients: Selective mismatching for HLA B 12, an antigen with variable expression on platelets.*Blood,* 74:1172-1176.

Semple, J.W., Italiano, Jr. J.E., Freedman, J. 2011. Platelets and the immune continuum. *Nat Rev Immunol*, 11:264–74.

Sharma, G. dan Berger, J. S. 2011. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. Journal of Thrombosis and Thrombolysis, 32(2): 201–208.

Shastry S. dan Chaudhary, R. 2012. Clinical factors influencing corrected count increment. *Transfus Apher Sci.* 47(3):327–330.

Shehata, N., Tinmouth, A., Naglie, G., Freedman, J. & Wilson, K. 2009. ABO-identical versus nonidentical platelet transfusion: a systematic review. *Transfusion*, 49, 2442–2453

Shrivastava, M. 2009. The platelet storage lesion. *Transfus Apher Sci*, 41:105-13.

Slichter, S.J. 1988. Platelet transfusion therapy. *Hematol Oncol Clin North Am*, 21(4):697-729.

Slichter, S.J.1990. *Mechanisms and Management of Platelet Refractoriness*, in Nan SJ (ed): Transfusion Medicine in the 1990's. Arlington, VA, American Association of Blood Banks, 95-179.

Stanworth, S.J., Navarrete, C. Estcourt, L., Marsh, J. 2015. Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. *British Journal of Haematology*, 171, 297–305

Sukorini, U., Rizki, M., 2010. Dasar-dasar Kontrol Kualitas Internal. In: Sukorini, U., Nugroho, D. K., Rizki, M., Hendriawan, B., editor, *Pemantauan Mutu Internal Laboratorium Klinik.*, Alfa Media, Yogyakarta. pp:13-38

Sut, C., Aloui, C., Tariket, S., *et al.* 2017. Assessment of soluble platelet CD40L and CD62P during the preparation process and the storage of apheresis platelet concentrates: Absence of factors related to donors and donations. *Tranfusion Clinique et Biologique*, xx:xx.

Sysmex Corporation, 2010. Automated Hematology Analyzer XN Series (For XN-1000 System) Instruction for Use. Sysmex Corporation, Kobe. pp: (7-1)-(15-34).

Thomas, M.R., dan Storey, R.F. 2015. The role of platelets in inflammation. Thrombosis and Haemostasis, 114(3):449–458.

tier Lelie V., Plas-Van, V., Dallen, C.M., Borne, V.K. 1984. AEGKr: Platelet autoantibodies in septicaemia. *Br J Hematol*, 58:755-758.

Tormey, C.A., Stack, G. 2014. Use of a cytokine-release assay to demonstrate loss of platelet secretory capacity during blood bank processing and storage. *Arch Pathol Lab Med* 138: 1481–7.

Triulzi, D.J., Assmann, S.F., Strauss, R.G., *et al*. 2012. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. *Blood*, 119:5553–62

UPTD RSUP Dr. Sardjito, 2016. *Laporan Pengeluaran Darah dan Rekapitulasi Pengeluaran Darah*. Yogyakarta.

van Bladel, E.R., Laarhoven, A.G., van der Heijden, L.B., *et al*. 2014. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. *Blood*, 123:1556-63.

van der Meer, P.F. dan de Korte, D. 2011. Platelet preservation: agitation and containers. *Transfus Apher Sci*, 44(3):297-304

Wencel-Drake, J.D., Boudignon-Proudhon, C., Dieter, M.G., Criss, A.B., Parise, L.V. 1996. Internalization of bound fibrinogen modulates platelet aggregation. *Blood*, 87:602.

Wood, L., Jogessar, V., Ward P., Jacobs, P. 2005. Estimation and predictive use of the corrected count increment–a proposed clinical guideline. *Transfus Apher Sci*, 32(1): 117–124.

World Health Organization. 2013. Global database on blood safety. Diunduh dari **:** **http://www.who.int/bloodsafety/global_database/en** , 2 Juni 2016.

World Health Organization, 2015. Blood safety and availability. *who.int/mediacentre/factsheets*, pp.1–8.